Intelligencia AI specializes in enhancing drug development through AI-powered solutions. The platform incorporates vast datasets to assess the probability of technical and regulatory success (PTRS). It enables organizations to de-risk clinical development by providing accurate assessments and insights across multiple therapeutic areas. Their AI tools, including the Portfolio Optimizer and Clinical Development Insights, aim to improve decision-making in pharmaceutical companies, identifying risks and optimizing trial designs. With explainable AI features, Intelligencia AI offers transparency in its assessments, helping professionals reduce uncertainty in drug development.
• high predictive accuracy for regulatory approvals
• robust data curation of over 1.5 billion data points
• transparent and explainable ai models
• portfolio optimizer and clinical development insights
• ai-powered solutions for clinical development
PTRS indicates the probability that a drug will move from one clinical phase to the next and achieve regulatory approval.
AI algorithms crunch large data sets to detect patterns and provide consistent, reliable results that traditional methods may miss.
The assessments boast an 80% prospective and 91% retrospective accuracy regarding the predictive accuracy of forecasting asset success.
Average Rating: 0.0
5 Stars:
0 Ratings
4 Stars:
0 Ratings
3 Stars:
0 Ratings
2 Stars:
0 Ratings
1 Star:
0 Ratings
No ratings available.
AI Healthtech for better and safer drug development using patient data insights.
View DetailsInnovative AI tool in the biotech sector optimizing drug development and improving patient outcomes.
View DetailsAI solutions for drug development, improving efficiency and outcomes in clinical trials.
View DetailsA federated AI framework that integrates decentralized data sources for AI development.
View Details